Autres langues Immix Biopharma, Inc.

Actions

IMMX

US45258H1068

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 02/05/2024			Varia. 5j.	Varia. 1 janv.
2,31 ^USD	+6,45%		+10,00%	-66,62%

29/04	Immix Biopharma obtient le label de médicament orphelin en Europe pour le traitement du myélome multiple	MT
18/04	Immix Biopharma, Inc. annonce qu'elle est en bonne voie pour administrer les doses de NXC-201 aux patients aux États-Unis	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment	29/04
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma	29/04
Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year	18/04
Immix Biopharma on Track to Dose NXC-201 Patients in United States	18/04
Immix Biopharma, Inc. Announces on Track to Dose NXC-201 Patients in United States	18/04
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy	16/04
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)	15/04
Immix Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial	20/03
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial	20/03
Immix Biopharma, Inc. Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 Al Amyloidosis Clinical Trial	20/03
Immix Biopharma Announces 'Be Proactive in AL' AL Amyloidosis Awareness Initiative	06/03
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative	05/03
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative	05/03
Immix Biopharma 12 Month Review Progress Update	21/02
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock	08/02
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock	08/02
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis	07/02
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis	07/02
Immix Biopharma Prices $15 Million Stock Offering	06/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Immix Biopharma, Inc.

Actions

IMMX

US45258H1068

Autres langues

Filtres